Serum magnesium, hepatocyte nuclear factor 1β genotype and post-transplant diabetes mellitus: a prospective study.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

This was a prospective study with measurements of serum magnesium and tacrolimus at pre-specified time points in the first year after living donor kidney transplantation (KT).

Repeated measurement and regression analyses were used to analyse associations with PTDM.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

The role of single nucleotide polymorphisms (SNPs) in hepatocyte nuclear factor 1β (HNF1β) was also explored because HNF1β regulates insulin secretion and renal magnesium handling.

What Was Measured

PubMed files the paper under topics including Biomarkers, Diabetes Mellitus, Genotype, Hepatocyte Nuclear Factor 1-beta, Immunosuppressive Agents, Kidney Transplantation and Magnesium.

The authors tagged it with the keywords calcineurin inhibitors, hypomagnesaemia, post-transplant diabetes mellitus, single nucleotide polymorphism and tacrolimus.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.